Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: yosid who wrote (2242)	1/22/2000 6:03:00 AM
From: Savant	Respond to of 3576

yosid, in lieu of any other response, I'll give it a shot. Gern should be able to handle the replication internally. It would seem to be a matter of allowing the natural cell division to take place, endlessly. The blood cell screening might not be applicable, other than selecting anomalous cell shapes. The internal deciding factors might not be amenable to screening via the other company's methodology. Good thinking though, maybe it would work. This is a layman's understanding, professionals feel free to eat me alive and correct my thoughts. Best, Savant ot..Prophet, remember a few of the other picks? Take the one that starts with M and wait a while.

To: yosid who wrote (2242)	1/22/2000 4:26:00 PM
From: LTK007	Read Replies (1) \| Respond to of 3576

ASTM,all i know is,while this sector is hot,ASTM is not---but i will study it,but it's lack of action makes me think it has a flaw somewhere,but i know nothing,are their replication claims well founded,if so,bears a serious look.. As for for the recommendation to sell GERN now because funds are unloading i give "the GERN misinformation of the year award"---any one who sold on that totally unconfirmed info,deserves to have got burned.max90